AI assistant
NovoCure Ltd — Director's Dealing 2022
Mar 8, 2022
31949_dirs_2022-03-07_183474d3-2786-43dd-a5fa-abd38c526612.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-03-03
Reporting Person: Weinberg Uri (Chief Science Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-03 | Ordinary Shares | A | 17371 | — | Acquired | 49186 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-03 | Options to Buy Ordinary Shares | $80.59 | A | 30422 | Acquired | 2032-02-29 | Ordinary Shares (30422.0) | Direct |
| 2022-03-03 | Options to Buy Ordinary Shares | $80.59 | A | 4961 | Acquired | 2032-02-29 | Ordinary Shares (4961.0) | Direct |
Footnotes
F1: Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F2: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F3: Options to buy 4,961 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.